Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dermata Therapeutics, Inc. (DRMA, DRMAW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret key points. Dermata operates in dermatology and medicinal and botanical manufacturing, and its filings reflect both its historical role as a late-stage biotechnology company and its more recent strategic pivot toward over-the-counter (OTC) pharmaceutical skin treatments.
Among the important documents are Form 8-K current reports detailing material events. For example, Dermata filed an 8-K describing its decision to prioritize the development and distribution of OTC pharmaceutical dermatology products, including plans to initially focus on a once-weekly acne kit that uses an OTC monograph active ingredient with the company’s Spongilla technology and the withdrawal of its investigational new drug application for XYNGARI™. Other 8-K filings address quarterly financial results, the implementation of a one-for-10 reverse stock split, and communications with The Nasdaq Stock Market regarding minimum bid price compliance and the granting of an exception period to regain compliance.
Through this page, users can review how Dermata reports its clinical progress, capital structure changes, and listing status directly to regulators. Forms related to results of operations, stock splits, and listing notices provide insight into the company’s financial condition and equity adjustments, while event-focused 8-Ks explain strategic decisions such as the OTC pivot. Stock Titan’s AI tools summarize lengthy filings, highlight significant sections, and help clarify terminology, allowing readers to quickly understand how each filing may relate to Dermata’s dermatology programs, OTC product plans, and Nasdaq-listed securities, including its DRMAW warrants.
Dermata Therapeutics, Inc. is shifting its strategy to focus on over-the-counter dermatology products that can be sold directly to consumers. The company plans to start with a once-weekly acne kit that combines an approved OTC monograph active ingredient with its Spongilla technology, targeting a launch in the middle of 2026, with additional OTC products expected afterward. As part of this pivot into the OTC marketplace, Dermata has withdrawn its investigational new drug application for XYNGARI™ with the U.S. Food and Drug Administration, moving away from that regulated prescription development path.
Dermata Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company had previously been notified on May 14, 2025 that its common stock failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days and that, because it had implemented a reverse stock split within the prior year, its securities were subject to potential delisting from the Nasdaq Capital Market.
After Dermata requested a hearing and was granted an exception until August 14, 2025 to regain compliance, Nasdaq staff notified the company on August 22, 2025 that it once again satisfies the minimum bid price requirement and that the matter is closed. This removes the previously disclosed risk that Dermata’s securities could be suspended or delisted from Nasdaq based on the minimum bid price issue.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 672,134 shares of Dermata Therapeutics, representing 9.99% of the class. The filing states Armistice Capital acts as investment manager to a Master Fund that directly holds the shares and that Armistice and Mr. Boyd share voting and dispositive power over those shares. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement. The filing affirms the position is held in the ordinary course of business and not for the purpose of changing control.
Dermata Therapeutics, Inc. reported unaudited second-quarter financials showing total assets of $6.64 million and cash and cash equivalents of $6.48 million as of June 30, 2025, which the company says will fund operations into the second quarter of 2026. The company recorded a net loss of $4.0 million for the six months ended June 30, 2025, and had an accumulated deficit of $69.7 million. Equity financing activity in early 2025 provided material cash inflows, including net proceeds of approximately $5.7 million from a warrant inducement and approximately $2.2 million from a January 2025 PIPE.
Clinical update: Dermata announced that its XYNGARI(TM) Phase 3 STAR-1 trial met all co-primary endpoints at week 12, with inflammatory lesion reductions of -16.8 versus -13.1 for placebo, noninflammatory lesion reductions of -17.3 versus -12.4 for placebo, and IGA responder rates of 29.4% versus 15.2% for placebo. Management notes a second Phase 3 trial (STAR-2) is required by the FDA. The company also discloses supply concentration risk (a Russian supplier) and Nasdaq minimum bid non-compliance with an exception period granted through August 14, 2025, creating ongoing listing risk.
On August 13, 2025 Dermata Therapeutics, Inc. submitted a Current Report on Form 8-K to furnish a press release that provides a corporate update and reports second quarter 2025 financial results for the quarter ended June 30, 2025. The filing identifies the press release as Exhibit 99.1 and an Interactive XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not "filed," and therefore is not subject to Section 18 liability or automatically incorporated by reference into future filings. The report is signed by CEO Gerald T. Proehl.